# Church & Dwight (CHD) — Financial Analysis

**Exchange:**   
**Coverage as of:** 2026-Q2  
**Updated:** 2026-06-03  
**Tier:** Free primer (step 2 of 19)  
**Sibling pages:** /stocks/CHD/thesis · /stocks/CHD/memo

## Financial Snapshot

---
source: coverage-next-full
ticker: CHD
step: "04"
title: Financial Quality & Adversarial Sweep
created: 2026-06-03
---

### Step 04 — Financial Quality & Adversarial Sweep: Church & Dwight Co. (CHD)

#### 1. Financial Statement Quality Assessment

##### Revenue Recognition
CHD recognizes revenue from product sales to retail customers per ASC 606 upon transfer of control. This is straightforward for a consumer goods company: revenue is recognized when product ships or is delivered to retailer. No complex multi-element arrangements or deferred revenue patterns that would distort reported revenue. [S1][S2]

**Revenue quality: HIGH.** No adjustments needed.

##### Gross Margin Adjustments
Reported gross margins are clean. The FY2022 compression (41.9%) and recovery (44.7% in FY2025) are genuine commodity-cycle effects, not accounting-driven distortions. No indication of channel stuffing or unsustainable pricing. [S1]

**Gross margin quality: HIGH.** Reported figures representative of underlying business.

##### Operating Income Adjustments

The two significant non-recurring items requiring normalization:

| Year | Non-Recurring Item | Amount | Impact |
|------|--------------------|--------|--------|
| FY2022 | Commodity + supply chain cost spike | Organic — no write-down, just genuine cost pressure | Depressed gross margin ~200 bps |
| FY2024 | VMS trade name impairment charge | -$357.1M | Depressed FY2024 operating income to $807M; adjusted ~$1,164M |
| Q3 2024 | VMS impairment concentrated in Q3 | -$357.1M | Drove Q3 2024 operating income to -$91.5M; net loss -$75.1M |

**Normalized Operating Income Estimates:**
| Year | Reported Op. Income | Adjustment | Normalized Op. Income |
|------|--------------------|-----------|-----------------------|
| FY2024 | $807M | +$357M (VMS impairment) | ~$1,164M (19.1% margin) |
| FY2025 | $1,078M | None | $1,078M (17.4% margin) |

FY2025 normalized operating margin (17.4%) is below FY2023 level (18.0%), reflecting the Touchland amortization drag and growth investments. This is a genuine temporary dilution from the $656M acquisition, not a quality concern. [S2][S3]

##### SBC Analysis
SBC jumped from $32M (FY2022) to $64M (FY2023) — the Hero acquisition-era compensation investment. SBC has stabilized at ~$58–63M (0.9–1.0% of sales), which is below industry median for CPG companies (typically 1.0–1.5%). Not a concern. [S1]

##### Goodwill & Intangibles
| Year | Goodwill | Other Intangibles | Total Intangibles | % of Assets |
|------|---------|------------------|------------------|----|
| FY2023 | $2,432M | $3,302M | $5,734M | 66.9% |
| FY2024 | $2,433M | $2,889M | $5,322M | 59.9% |
| FY2025 | $2,628M | $3,512M | $6,140M | 68.9% |

The FY2025 increase in Goodwill (+$195M) and Other Intangibles (+$623M) reflects the Touchland acquisition ($656M net purchase price). The VMS write-down in FY2024 reduced Other Intangibles by ~$357M, bringing them from $3,302M to $2,889M; the subsequent FY2025 Touchland addition rebuilt them to $3,512M. [S1][S2]

**Impairment risk assessment:** The VMS write-down was specific to a single brand (VITAFUSION/gummies) in a private-label-pressured category. CHD's remaining intangibles are concentrated in HERO (high-growth), THERABREATH (gaining share), WATERPIK (75% share), and TROJAN (70% share) — brands with stronger competitive moats. Near-term impairment risk is low but not zero for BATISTE (losing domestic share). [Judgment]

##### Working Capital & Cash Conversion
| Metric | FY2025 | FY2024 |
|--------|--------|--------|
| Accounts Receivable | $593M (35 DSO) | $601M (36 DSO) |
| Inventory | $535M (57 DIO) | $613M (67 DIO) |
| Accounts Payable | $732M (78 DPO) | $705M (78 DPO) |
| Net Working Capital | $396M | $509M |
| Cash Conversion Cycle | ~14 days | ~25 days |

Working capital efficiency improved in FY2025 (inventory down $78M as destocking cleared), contributing to the FCF expansion. DPO of ~78 days is typical for large CPG companies with significant retailer leverage. [S3]

#### 2. Adversarial Research Sweep

*Investigation of short reports, SEC investigations, lawsuits, accounting irregularities, and reputational risks.*

##### Active Short Positions / Short Reports
**No significant active short thesis identified** on CHD as of June 2026. CHD short interest is approximately 1.2–1.5% of float, which is minimal for a large-cap Consumer Staples company. No prominent short seller has published a public attack report on CHD in recent years. [S6]

##### Historical Litigation & Regulatory Actions
| Matter | Status | Materiality |
|--------|--------|------------|
| TROJAN (sexual wellness) — no known product liability mass litigation | Clean | Immaterial |
| ARM & HAMMER cat litter — class actions re: sodium dust/clumping performance | Settled historically; no active cases identified | Immaterial |
| SEC investigation or accounting inquiry | None identified | None |
| FTC/DOJ antitrust (serial M&A) | No known formal investigations | Immaterial |

**Conclusion:** No material active litigation identified. CHD's legal profile is typical for a large consumer goods company: routine product liability claims resolved through insurance, no pattern of material lawsuits or regulatory enforcement. [S2]

##### Product Safety Concerns
- TROJAN is an FDA-regulated Class II device (condoms as medical devices); no significant recalls or adverse action history
- ZICAM zinc product litigation resulted in product reformulation (prior to CHD's divestiture of ZICAM); CHD retained the reformulated product but has since divested it — removing this risk
- HERO acne patches are cosmetics/OTC; no material safety concerns identified
- WATERPIK is FDA-registered for dental irrigation; no material recalls

##### Management Integrity Assessment
- **CEO transition** (Farrell → Dierker 2025) was planned and disclosed proactively; no abrupt resignation signals
- **Farrell share sales ($62M over 6 months):** Consistent with documented retirement plan (10b5-1); timing pre-dates retirement confirmation; flagged but not an integrity signal
- **Dierker open-market purchase ($501K Aug 2025):** Positive conviction signal post-appointment
- **Financial guidance track record:** FY2025 was CHD's first meaningful guidance downgrade in several years (organic growth from 3–4% to 0–2%); management was transparent in disclosing the headwinds. No evidence of sandbagging or inflated guidance patterns. [S4][S7]

##### Quality of Acquisition Track Record
CHD's acquisitions have predominantly been value-creative with limited write-down history until the VMS (VITAFUSION) impairment:
| Acquisition | Year | Written Down? | Assessment |
|-------------|------|--------------|-----------|
| Waterpik | 2017 | No | Strong value creation (75% share) |
| THERABREATH | 2021 | No | Strong value creation (#2 mouthwash) |
| Hero Cosmetics | 2021 | No | Strong value creation; international expansion |
| VITAFUSION / VMS brands | 2012-era + Hero-era | YES ($357M FY2024) | Private label disruption caused impairment |
| FLAWLESS | 2019 | Divested 2025 | Disappointing; divested |
| TOUCHLAND | 2025 | Too early to assess | Management: premium personal care alignment |

One meaningful impairment in 15+ acquisitions is a strong track record. VITAFUSION was the exception, not the rule. [S2][Judgment]

##### Revenue Quality / Channel Check
No evidence of channel stuffing or unsustainable sell-in. FY2025 retail destocking (Consumer Domestic organic ~0.4%) confirmed end-consumer demand was soft, not pump-priming inventory at retail. Q1 2026 organic acceleration (+5%) with volume-driven growth across all three divisions confirms the destocking was a one-time inventory cycle, not demand structural deterioration. [S4]

#### 3. Key Financial Quality Conclusion

| Dimension | Rating | Notes |
|-----------|--------|-------|
| Revenue recognition | Clean | Standard CPG; no concerns |
| Gross margin | Clean | Commodity cycle, not accounting |
| Non-recurring items | Identified | FY2024 VMS impairment; normalized |
| SBC | Acceptable | 0.9% of sales; not dilutive |
| Working capital | Improving | Destocking drove FCF expansion |
| Intangibles / goodwill | Elevated | 68% of assets; M&A model; one impairment |
| Litigation / regulatory | Clean | No material active matters |
| Management integrity | Positive | Dierker conviction buy; no red flags |
| Overall quality | **HIGH** | Adjust FY2024 for impairment; FY2025 clean |

#### Source Index

| ID | Source | Type | Date |
|----|--------|------|------|
| S1 | SEC EDGAR XBRL (CIK 0000313927) | Primary | 2026-06-03 |
| S2 | CHD 10-K FY2025 + FY2024 | Primary | 2026-06-03 |
| S3 | StockAnalysis.com | Secondary | 2026-06-03 |
| S4 | CHD Q1 2026 Earnings Release (8-K) | Primary | 2026-06-03 |
| S5 | CHD DEF 14A 2025 | Primary | 2026-06-03 |
| S6 | Short interest data, competitive research | Secondary | 2026-06-03 |
| S7 | Form 4 insider transactions | Primary | 2026-06-03 |

*Note: Earnings call transcript analysis not performed — coverage-next-full path. Commentary on management tone sourced from 8-K press releases and investor presentations.*

## Deeper Financial Analysis

The fundamental tier ($1.00) adds 8 dimensions not included here:

- Revenue Breakdown — segment revenue, geographic mix, product-line margins
- Financial Trends — QoQ momentum, leading indicators, inflection points
- Balance Sheet — debt structure, dilution risk, working capital dynamics
- Capital Allocation — ROIC, buyback cadence, reinvestment efficiency
- Earnings Analysis — beats/misses, guidance vs actuals, transcript highlights
- Competitive Positioning — market share, pricing power, peer benchmarks
- Industry Context — TAM, sector tailwinds/headwinds, regulatory backdrop

**API endpoint:** GET /api/v1/research/CHD/fundamental

## Navigation

- Overview: /stocks/CHD
- Financials (this page): /stocks/CHD/financials
- Thesis: /stocks/CHD/thesis
- Investment Memo: /stocks/CHD/memo
- Coverage universe: /stocks